Fig 6.
Therapeutic treatment of infected guinea pigs with HSV-2 antigens or GEN-003 vaccine. Guinea pigs were infected intravaginally with 5 × 105 PFU of HSV-2 strain MS, allowed to recover from primary disease, and then vaccinated s.c. three times on days 14, 21, and 36 postinfection. (A and B) PBS (n = 9), 50 μg of MM-2 alone (n = 12), and 15 μg of each antigen alone plus 50 μg of MM-2 adjuvant (n = 9 to 11) (Table 1, experiment 1). (A) Cumulative mean lesion severity scores (as described in Materials and Methods) are shown for each group. (B) The number of days with a recurrent lesion is shown. Each symbol indicates an individual animal from the same group. The P value compares the PBS control group to each antigen-immunized group using unpaired, two-tailed Student's t test. (C and D) Fifteen micrograms of each antigen (GEN-003) or 15 μg of each antigen plus 50 μg of MM-2 (GEN-003/MM-2) (Table 1, experiment 2). (C) Cumulative mean lesion severity scores (as described in Materials and Methods) are shown for each group: PBS (n = 13), GEN-003 (n = 14), and GEN-003/MM-2 (n = 11). (D) The number of days with a recurrent lesion is shown. Each symbol indicates individual animals from the same group. The P value compares the PBS control group to the GEN-003 or GEN-003/MM-2 vaccine-immunized group using unpaired, two-tailed Student's t test. (E and F) Fifty micrograms of MM-2 or 15 μg of gD2ΔTMR plus 15 μg of ICP4383-766 with 50 μg of MM-2 (GEN-003/MM-2). (E) Cumulative mean lesion severity scores are shown for each group: MM-2 (n = 19) and GEN-003/MM-2 (n = 20). (F) The number of days with a recurrent lesion is shown. Each symbol indicates an individual animal from the same group. P values compare the GEN-003/MM-2-vaccinated group to the MM-2 control group using unpaired, two-tailed Student's t test.